# CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

> **NCT00634751** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 48 (actual)

## Conditions studied

- Pancreatic Neoplasms
- Bile Duct Neoplasms

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00634751
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-11-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00634751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00634751, "CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00634751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*